Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.54B | 3.52B | 2.36B | 1.55B | 1.19B |
Gross Profit | 4.55B | 2.95B | 2.00B | 1.35B | 1.01B |
EBITDA | 2.31B | 1.78B | 1.21B | 938.78M | 674.10M |
Net Income | 2.06B | 1.45B | 1.00B | 828.13M | 826.45M |
Balance Sheet | |||||
Total Assets | 8.04B | 4.97B | 3.14B | 7.88B | 2.65B |
Cash, Cash Equivalents and Short-Term Investments | 5.86B | 3.78B | 2.20B | 7.26B | 1.96B |
Total Debt | 6.71M | 2.73M | 2.59M | 0.00 | 0.00 |
Total Liabilities | 918.14M | 602.03M | 301.19M | 6.86B | 2.19B |
Stockholders Equity | 7.11B | 4.36B | 2.83B | 1.02B | 458.00M |
Cash Flow | |||||
Free Cash Flow | 1.79B | 1.42B | 778.39M | 581.21M | 757.79M |
Operating Cash Flow | 2.04B | 1.65B | 931.64M | 692.40M | 834.12M |
Investing Cash Flow | -1.11B | -527.28M | -858.74M | 1.56B | -521.12M |
Financing Cash Flow | 582.95M | 51.81M | -5.79B | 4.48B | -17.52M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | HK$33.83B | 38.53 | 37.28% | 0.98% | 59.83% | 68.29% | |
74 Outperform | €3.52B | 15.96 | 6.78% | 5.60% | 9.45% | 12.30% | |
72 Outperform | $26.96B | 10.62 | 11.12% | 6.44% | -6.53% | -18.43% | |
64 Neutral | HK$61.13B | 26.02 | 36.16% | 1.11% | 54.44% | 35.90% | |
59 Neutral | HK$15.54B | 5.61 | -7.44% | 4.07% | 11.55% | -28.15% | |
54 Neutral | HK$24.09B | ― | -7.87% | 2.92% | 16.82% | -348.71% | |
48 Neutral | HK$1.12B | ― | -20.26% | ― | 5.25% | -581.58% |
Giant Biogene Holding Co., Ltd., a company incorporated in the Cayman Islands, has announced an increase in shareholding by its controlling shareholder, Juzi Holding Co., Ltd. This move is intended to demonstrate confidence in the company’s future development and promote sustainable growth. Juzi Holding has purchased 1,056,600 shares, raising its total ownership to 54.36% of the company’s issued shares. This strategic action is aimed at safeguarding public investors’ interests and may be subject to further increases based on market conditions.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced that its controlling shareholder, Juzi Holding Co., Ltd, has increased its shareholding by purchasing 922,600 shares at a total cost of HK$46.7 million. This move demonstrates confidence in the company’s future development and aims to promote its sustainable growth while safeguarding public investors’ interests. Juzi Holding now holds 54.35% of the company’s total issued shares and may further increase its stake, depending on market conditions.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd. has announced a special cash dividend of RMB 0.5921 per share for the financial year ending December 31, 2024, with the payment to be made in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09357. This announcement reflects the company’s robust financial performance and commitment to delivering value to its shareholders, potentially enhancing its market position and investor confidence.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd held its Annual General Meeting on June 13, 2025, where all proposed resolutions were approved by shareholders. Key outcomes include the re-election of directors, re-appointment of Ernst & Young as auditors, and authorization for the board to manage share repurchases and issuances. Additionally, the company announced the distribution of a final and special dividend for the year ended December 31, 2024, reflecting strong shareholder support and financial stability.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced an update to its final cash dividend for the year ended December 31, 2024, with a declared dividend of RMB 0.6021 per share. The dividend will be paid in Hong Kong dollars at a rate of HKD 0.6584 per share, with the payment date set for August 29, 2025. This update reflects changes in the default currency and exchange rate, potentially impacting shareholders’ returns and the company’s financial distribution strategy.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd announced that its controlling shareholder, Juzi Holding Co., Ltd, plans to increase its shareholding in the company by at least HK$200 million within the next three to six months. This move reflects Juzi Holding’s confidence in the company’s growth potential and commitment to its future prospects, while ensuring a sufficient public float of shares.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
Giant Biogene Holding Co., Ltd. has announced its upcoming annual general meeting scheduled for June 13, 2025, in Xi’an, Shaanxi Province, China. The meeting will address several key resolutions, including the re-election of independent non-executive directors, re-appointment of Ernst & Young as auditors, and granting general mandates for share repurchase and issuance. These resolutions are expected to impact the company’s governance and financial strategies, potentially influencing its market positioning and shareholder value.
Giant Biogene Holding Co., Ltd announced the completion of a Vendor Placing and Subscription of new shares under a general mandate. The company successfully placed 35,000,000 shares at HK$66.65 per share, raising approximately HK$2,294 million. The proceeds will be used to develop the company’s core business, including brand promotion, marketing, category expansion, and R&D investment, as well as to replenish liquidity and support general corporate purposes.
Giant Biogene Holding Co., Ltd. announced a placing and top-up subscription agreement involving 35 million shares at HK$66.65 per share, expected to raise approximately HK$2,294 million in net proceeds. The funds will be used to enhance the company’s financial strength, market competitiveness, and shareholder base, supporting long-term sustainable development and liquidity.